The treatment of co-morbidities in older patients with metastatic cancer

Supportive Care in Cancer

Volumn 18, Issue 5, 2010, Pages 651-655

  Cashman, Josephine ^a   Wright, Juliet ^a   Ring, Alistair ^b  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

Cancer; Co morbidities; Geriatric oncology; Polypharmacy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

AGED; AGING; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR DISEASE; COLON CANCER; COMORBIDITY; DIZZINESS; FEMALE; GASTRITIS; GROUPS BY AGE; HUMAN; HYPERTENSION; INDIGESTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MYALGIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SKIN BRUISING; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; COMORBIDITY; ENGLAND; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICAL AUDIT; NEOPLASM METASTASIS; PATIENT COMPLIANCE; POLYPHARMACY;

EID: 77953619300     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0813-1     Document Type: Article

References (12)

1. DeVita VT, Lawrence TS, Rosenberg SA (2008) Cancer:pr in ciples and practice of oncology, 8th edn. Lipp in cott Williamsand WilKins, Philadelphia
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A,Krook J et al (2002) Comparisonof four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2):92-98 (Pubitemid 34438899)
3. O'Shaughnessy J (2005) ExtenDing survival with chemotherapy in metastatic breast cancer. Oncologist 10 (Suppl 3):S20-S29
4. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess Vet al (2008) AdDing cetuximab to capecitab ine plus oxaliplat in (XELOX) in first-line treatment of metastatic colorectal cancer: Arandomized phase II trial of the Swiss Group for Clin ical CancerResearch Sa KK. Annoncol 19 (7):1288-1292
5. Cancer Research UK (2008) UK cancer in cidence statistics by age. Cited 2009 May 9. http://info.cancerresearchuk.org/cancerstats/in cidence/age/
6. Khaw K-T (1999) How many, how old, how soon? BMJ 20 (319):1350-1352
7. Wolff JL, Starfield B, Andersong (2002) Prevalence, expendi-tures, and complications of multiple chronic conditions in the elderly. Arch in tern Med 162 (20):2269-2276
8. Stevenson J, Abernethy AP, Miller C, Currow DC (2004) Manag ing comorbidities in patients at the end of life. BMJ 329 (7471):909-912
9. Mannesse CK, Derkx FHM, De Ridder MAJ, Manin'tVeld AJ,Vander Cammen TJM (2000) Contributionof adverse drug reactions to hospital admissions of older patients. Age Age ing 29 (29):35-39
10. Rollason V, Vogt N (2003) Reductionof polypharmacy in the elderly: A systematic review of therole of the pharmacist. Drugs Ag ing 20 (11):817-832
11. Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug-drug anddrug-disease in teractions in the ED: Analysis of a high-risk population. Am J Emerg Med 14 (5):447-450
12. Koh Y, Kutty FB, Li SC (2005) Drug-related problems in hospitalized patients on polypharmacy: The in fluence of age andgender. ther Clin Risk Manag 1 (1):39-48